Peptide nucleic acids as therapeutic agents.
Peptide nucleic acids (PNAs) have been around for more than seven years and it was hoped, at their introduction, that they would quickly enter the fields of antisense and antigene technology and drug development. Despite their extremely favorable hybridization and stability properties, as well as the encouraging antisense and antigene activity of PNA in cell-free systems, progress has been slow and experiments on cells in culture and in animals have been lacking. Judging from the very promising results published within the past year, however, there is every reason to believe that both PNA antisense and, possibly, PNA antigene research will strongly pick up momentum again. Specifically, it has been demonstrated that certain peptide-PNA conjugates are taken up very efficiently by, at least some, eukaryotic cells and that antisense down regulation of target genes in nerve cells in culture is attainable using such PNA conjugates. Perhaps even more exciting is that antisense-compatible effects have been reported using PNAs injected into the brain of rats. Finally, it has been shown that the bacterium Escherichia coli is susceptible to antisense gene regulation using PNA.
Nielsen
P E
PE
Center for Biomolecular Recognition, Department of Medical Biochemistry and Genetics, The Panum Institute, Copenhagen, Denmark. pen@imbg.ku.dk
D000818:Animals; D012321:DNA-Directed RNA Polymerases / Q000037:antagonists & inhibitors; D005057:Eukaryotic Cells / Q000737:chemistry; D006801:Humans; D016376:Oligonucleotides, Antisense / Q000737:chemistry / Q000494:pharmacology / Q000627:therapeutic use; D010441:Peptide Chain Elongation, Translational / Q000187:drug effects; D020135:Peptide Nucleic Acids / Q000737:chemistry* / Q000494:pharmacology / Q000627:therapeutic use*; D011387:Prokaryotic Cells / Q000737:chemistry
D016376:Oligonucleotides, Antisense; D020135:Peptide Nucleic Acids; D012321:DNA-Directed RNA Polymerases